Open-label, single-arm phase Ib/II study of immune combination therapy with elotuzumab and belantamab mafodotin in patients with relapsed refractory multiple myeloma

被引：0
|
作者：
Browning, Sabrina
Li, Fangyong
Parker, Terri L.
Bar, Noffar
Anderson, Tara
Stevens, Erica
VanOudenhove, Jennifer
Matthews, Martin
Gorshein, Elan
Talsania, Ashita D.
Sabbath, Kert D.
Seropian, Stuart
Halene, Stephanie
Neparidze, Natalia
机构：
[1] Yale Sch Med, Div Hematol, Dept Internal Med, New Haven, CT USA
[2] Yale Sch Publ Hlth, New Haven, CT USA
[3] Yale New Haven Hosp, New Haven, CT USA
[4] Yale Univ, Div Hematol, New Haven, CT USA
[5] Yale Canc Ctr, Div Hematol, New Haven, CT USA
[6] Yale Univ, Div Hematol, Shool Med, New Haven, CT USA
[7] Yale Univ, New Haven, CT USA
[8] Yale Univ, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7559
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
    Hultcrantz, Malin
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Maclachlan, Kylee H.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Akhlaghi, Theresia
    Hamadeh, Issam S.
    Chung, David J.
    Lahoud, Oscar B.
    Landau, Heather
    Scordo, Michael
    Shah, Gunjan L.
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Usmani, Saad
    BLOOD, 2022, 140 : 7246 - 7248
  • [32] An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
    Vij, Ravi
    Wang, Michael
    Kaufman, Jonathan L.
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Stewart, A. Keith
    Kukreti, Vishal
    Jagannath, Sundar
    McDonagh, Kevin T.
    Alsina, Melissa
    Bahlis, Nizar J.
    Reu, Frederic J.
    Gabrail, Nashat Y.
    Belch, Andrew
    Matous, Jeffrey V.
    Lee, Peter
    Rosen, Peter
    Sebag, Michael
    Vesole, David H.
    Kunkel, Lori A.
    Wear, Sandra M.
    Wong, Alvin F.
    Orlowski, Robert Z.
    Siegel, David S.
    BLOOD, 2012, 119 (24) : 5661 - 5670
  • [33] Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study
    Deng, Li-Juan
    Zhou, Ke-Shu
    Liu, Li-Hong
    Zhang, Ming-Zhi
    Li, Zhi-Ming
    Ji, Chun-Yan
    Xu, Wei
    Liu, Ting
    Xu, Bing
    Wang, Xin
    Gao, Su-Jun
    Zhang, Hui-Lai
    Hu, Yu
    Li, Yan
    Cheng, Ying
    Yang, Hai-Yan
    Cao, Jun-Ning
    Zhu, Zun-Min
    Hu, Jian-Da
    Zhang, Wei
    Jing, Hong-Mei
    Ding, Kai-Yang
    Zhang, Xiang-Yang
    Zhao, Ren -Bin
    Zhang, Bin
    Tian, Ya -Min
    Song, Yong-Ping
    Song, Yu-Qin
    Zhu, Jun
    BLOOD ADVANCES, 2023, 7 (16) : 4349 - 4357
  • [34] Everolimus for Relapsed/Refractory Classical Hodgkin Lymphoma: Multicenter, Open-Label, Single-Arm, Phase 2 Study
    Johnston, Patrick B.
    Pinter-Brown, Lauren
    Rogerio, Jaqueline
    Warsi, Ghulam
    Chau, Quincy
    Ramchandren, Radhakrishnan
    BLOOD, 2012, 120 (21)
  • [35] Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial
    Kroiss, Matthias
    Quinkler, Marcus
    Johanssen, Sarah
    van Erp, Nielka P.
    Lankheet, Nienke
    Poellinger, Alexander
    Laubner, Katharina
    Strasburger, Christian J.
    Hahner, Stefanie
    Mueller, Hans-Helge
    Allolio, Bruno
    Fassnacht, Martin
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (10): : 3495 - 3503
  • [36] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
    Richardson, P
    Jagannath, S
    Hussein, M
    Berenson, J
    Singhal, S
    Irwin, D
    Williams, SF
    Bensinger, W
    Badros, AZ
    Vescio, R
    Kenvin, L
    Yu, ZN
    Olesnyckyj, M
    Faleck, H
    Zeldis, J
    Knight, R
    Anderson, KC
    BLOOD, 2005, 106 (11) : 449A - 449A
  • [37] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [38] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
    Roussel, Murielle
    Texier, Nathalie
    Germain, Raphael
    Sapra, Sandhya
    Paka, Prani
    Kerbouche, Naima
    Colin, Xavier
    Leleu, Xavier
    BLOOD, 2022, 140 : 4261 - 4263
  • [39] DREAMM-3: a phase III, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in Relapsed/ Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Dimopoulos, M. A.
    Hungria, V. T. M.
    Radino, A.
    Delimpasi, S.
    Mikala, G.
    Masszi, T.
    Li, J.
    Capra, M.
    Matsumoto, M.
    Sule, N.
    Li, M.
    McKeown, A.
    He, W.
    Bright, S.
    Currie, B.
    Boyle, J.
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 233 - 234
  • [40] Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
    Nooka, Ajay K.
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Routledge, David
    Otero, Paula Rodriguez
    Song, Kevin
    Quach, Hang
    Callander, Natalie
    Minnema, Monique C.
    Trudel, Suzanne
    Jackson, Nicola A.
    Ahlers, Christoph M.
    Im, Ellie
    Cheng, Shinta
    Smith, L.
    Hareth, Nahi
    Ferron-Brady, Geraldine
    Brouch, Maria
    de Oca, Rocio Montes
    Paul, Sofia
    Holkova, Beata
    Gupta, Ira
    Kremer, Brandon E.
    Richardson, Paul
    FUTURE ONCOLOGY, 2021, 17 (16) : 1987 - 2003
12345